When Chouaib MEZIADI and I founded Core Biogenesis in 2020, we had a clear vision to revolutionize how recombinant proteins are produced by harnessing the power of plants. 🌱
The platform technology we’ve developed over the years is not only more sustainable and scalable but also extremely broad in its potential. ⏩
Our first products are targeted to the life science and bioprocessing industries, where our technology quickly proved its value. 🧬
I’m excited to share that we are now expanding our product offerings beyond the Life Sciences as we'll soon officially launch new products for the Cosmeceutical industry, leveraging the exact same platform technology that has served us so well.
The potential applications of Core Biogenesis technology are vast, and I can't wait to tell you more about our upcoming launch! 💥
Engineering the Future of Solid Tumour Immunotherapy: iPSC-derived Macrophages Boost T Cell Efficacy
Here's our pick of the presentations at the International Society for Stem Cell Research 2024 meeting in Germany last month.
Ian Hay at Factor Bioscience Inc. gave an incredible presentation showcasing research that could revolutionize the treatment of solid tumours.
At the heart of this innovation is a novel method for producing macrophages from induced pluripotent stem cells (iPSCs). Hay described an optimized 28-day protocol that is both feeder-free and xeno-free, making it amenable to GMP-compliant production.
Thanks for sharing, Ian!
The full article is below if i-macrophages are your thing...
#celltherapy#stemcells#iPSC
#ISSCR2024 was full of promise and innovation! ✨
There was a huge amount of research and clinical development on display, especially in the #iPSC space 🧫. We've distilled all of this down into a couple of trends and innovations worth following, here are our two overarching trends to watch:
1. Single Cell Technologies, Molecular Insights, and Predictive AI tools
2. Complex 3D models, and Best Practices on Drug Screening Platforms for Inclusive Therapeutic Developments
Did you attend? What were your thoughts?
#ISSCR24#stemcellresearch#celltherapy#sciencemeetsai
#ISSCR2024 was full of promise and innovation! ✨
There was a huge amount of research and clinical development on display, especially in the #iPSC space 🧫. We've distilled all of this down into a couple of trends and innovations worth following, here are our two overarching trends to watch:
1. Single Cell Technologies, Molecular Insights, and Predictive AI tools
2. Complex 3D models, and Best Practices on Drug Screening Platforms for Inclusive Therapeutic Developments
Did you attend? What were your thoughts?
#ISSCR24#stemcellresearch#celltherapy#sciencemeetsai
🧫🔬 𝐈𝐧𝐯𝐞𝐬𝐭𝐢𝐠𝐚𝐭𝐢𝐧𝐠 𝐏𝐥𝐮𝐫𝐢𝐩𝐨𝐭𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐫 𝐄𝐱𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐔𝐧𝐝𝐞𝐫 𝐃𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭 𝐆𝐫𝐨𝐰𝐭𝐡 𝐅𝐚𝐜𝐭𝐨𝐫 𝐂𝐨𝐧𝐜𝐞𝐧𝐭𝐫𝐚𝐭𝐢𝐨𝐧𝐬 𝐚𝐧𝐝 𝐅𝐞𝐞𝐝𝐢𝐧𝐠 𝐂𝐨𝐧𝐝𝐢𝐭𝐢𝐨𝐧𝐬
Following the cell morphology and proliferation analysis examined in the past few posts, we went on to analyse pluripotency.
The effects and capacity of FGF-2 TOP® to maintain high-quality iPSC cultures under different concentrations and media feeding regimes were assessed by determining the expression of key markers of pluripotency:
OCT4
NANOG
SSEA5
SSEA4
The results show that FGF-2 TOP® presents a superior performance for culturing iPSCs and allows you to reduce media feeding – including weekend-free schedules - without compromising the quality and pluripotency of the cells in culture.
The details of the flow cytometry approach and different culture conditions can be found in the study - https://lnkd.in/eM6Hm7kR
📈 𝐢𝐏𝐒𝐂 𝐏𝐫𝐨𝐥𝐢𝐟𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 📈
We assessed the growth rates of iPSCs under different concentrations of both 'wild-type' human recombinant FGF-2 and recombinant FGF-2 TOP®(Thermostability Optimized) using cell proliferation assays.
After 5 days in culture, the lower concentration (50 ng/mL) promoted an average amplification rate of 73% for human recombinant FGF-2, while for recombinant FGF-2 TOP® the amplification rate corresponded to 82%.
The effects of adding a higher concentration of 100 ng/mL resulted in an amplification rate of 83% and 85% for human recombinant FGF-2, and FGF- 2 TOP® respectively.
Further analysis with every other day (EOD) media replacement, demonstrated the capacity of FGF-2 TOP® to keep high proliferation rates of iPSCs even under reduced feeding schedules.
Conclusion – Thanks to the thermal stability of FGF-2 TOP®, less FGF-2 is needed for comparable proliferation rates, contributing to lower costs and more flexible culture operations.
You can find the study here – https://lnkd.in/eM6Hm7kR
📣 𝐢𝐏𝐒𝐂𝐬 𝐒𝐮𝐩𝐩𝐥𝐞𝐦𝐞𝐧𝐭𝐞𝐝 𝐰𝐢𝐭𝐡 𝐅𝐆𝐅-2 𝐓𝐎𝐏® 𝐃𝐢𝐬𝐩𝐥𝐚𝐲 𝐍𝐨𝐫𝐦𝐚𝐥 𝐏𝐥𝐮𝐫𝐢𝐩𝐨𝐭𝐞𝐧𝐭 𝐌𝐨𝐫𝐩𝐡𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐏𝐡𝐞𝐧𝐨𝐭𝐲𝐩𝐞𝐬 📣
The recent study into a thermostable version of FGF-2 (FGF-2 TOP®) examined the quality of iPSC cultures under different media conditions by morphological appearance under the microscope.
This method was also applied to observe any spontaneous differentiation, which would indicate non-optimal cell culture conditions to preserve the pluripotent profile of iPSCs.
🔬You can see the microscopy images below, for the results and methodologies take a look at the publication –
https://lnkd.in/eM6Hm7kR
📖 New Study: 𝐄𝐯𝐚𝐥𝐮𝐚𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐮𝐬𝐞 𝐨𝐟 𝐓𝐡𝐞𝐫𝐦𝐨𝐬𝐭𝐚𝐛𝐥𝐞 𝐅𝐆𝐅-2 (𝐅𝐆𝐅-2 𝐓𝐎𝐏®) 𝐟𝐨𝐫 𝐨𝐩𝐭𝐢𝐦𝐢𝐳𝐞𝐝 𝐢𝐏𝐒𝐂 𝐂𝐮𝐥𝐭𝐮𝐫𝐞 𝐏𝐫𝐨𝐭𝐨𝐜𝐨𝐥𝐬
iPSC culture requires FGF-2 to maintain pluripotency, but it comes at a cost.
The FGF-2 protein is inherently unstable - <10 hours half-life! - leading to difficulties sustaining signalling cues for pluripotency.
The result: daily media changes, which are a constant barrier for researchers and therapy developers.
🧫 So, can we enhance the efficiency and cost-effectiveness of iPSC culture techniques?
We think so.
🌡️ Our thermostable version of FGF-2 comes with an enhanced half-life (> 7 days at 37ºC), developed by computer-assisted engineering, licensed from Enantis. The result is a new variant with 9-point amino acid substitutions that preserves the full bioactivity and signalling required for FGF-2-mediated pathways.
You can delve into the details in this new study created in partnership with TreeFrog Therapeutics, which includes:
- evaluation of the performance of this thermostable version of FGF-2
- its effectiveness at maintaining high-quality iPSC cultures
- a move towards optimized cell feeding schedules
Find out more - https://lnkd.in/eM6Hm7kR
🗣 Exciting news for our collaborators and #stemcell scientists working with FGF-2…
We have rebranded our star product: The Thermostable FGF-2, formerly known as STAB, now is named...
👇👇👇
*FGF-2 TOP® (Thermostability Optimized)
As a crucial factor to obtain high quality cultures during #stemcell expansion (#pluripotent and #mesenchymal) and differentiation (#neural, #myogenic, #endothelial), the heat stable version of FGF-2 with extended half-life (>7days) at 37ºC is becoming the new gold-standard for the field 🧪
However, to date very few options are available on the market, and most of them come with inconsistent quality attributes, or are offered at very high costs - thus impeding the progress of advanced stem cell science 🔬
Since we got the license for the patented engineered sequence of the #ThermostableFGF2 from Enantis, at Core Biogenesis we have proven a solid track record for enabling scientists to optimize their stem cell culture protocols, while offering the only available product at lower price - 50-70% less than market average, thanks to our sustainable biomanufacturing platform 🌱
Now, is the perfect time to give our product the credit it deserves, and stand-out from the rest! Choosing TOP (Thermostability Optimized) was an easy decision thanks to the 👉
▪️ TOP Performance 🥇
▪️ TOP Results 🧫
▪️ TOP Users 👩🔬👨🔬
*All the product specifications and formats are preserved as before, with the only difference of the new name 🔝
Join us in our mission to improve current lab protocols and democratise the access to advanced stem cell science 🙌
If you are interested in FGF-2 TOP® or want to learn more, contact us: https://lnkd.in/eJ3DcmiW#stemcellresearch#pluripotentstemcells#thermostablefgf2#productrebranding